Late-onset myasthenia gravis: A changing scene

Archives of Neurology

Volumn 56, Issue 1, 1999, Pages 25-27

  Aarli, Johan A ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CONNECTIN; IMMUNOSUPPRESSIVE AGENT; MUSCLE ANTIBODY; MUSCLE ANTIGEN; STEROID;

COMORBIDITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; HUMAN; MYASTHENIA GRAVIS; MYOPATHY; ONSET AGE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; SKELETAL MUSCLE; STEROID THERAPY; THYMECTOMY; THYMOMA; TREATMENT INDICATION;

AGE OF ONSET; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NORWAY; PREVALENCE;

EID: 0032958983     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.1.25     Document Type: Review

References (31)

1. Aird RB. Muscular atrophies and dystrophies. In: Baker AB, ed. Clinical Neurology. Vol 3. New York. NY: Hoeber & Harper; 1955:1498-1562.
2. Campbell H, Bramwell E. Myasthenia gravis. Brain. 1900;23:277-336.
3. Schwab RS, Leland CC. Sex and age in myasthenia gravis as critical factors in incidence and remission. JAMA. 1953;153:1270-1273.
4. Simpson JF, Westerberg MR, Magee KR. Myasthenia gravis: an analysis of 295 cases. Acta Neurol Scand. 1966;42(suppl 23):1-27.
5. Christensen PB, Jensen TS, Tsiropoulos I, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology. 1993;43:1779-1783.
6. Phillips LH, Torner JC, Anderson MS, Cox CG. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42:1888-1893.
7. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47:1233-1238.
8. Schon F, Drayson M, Thompson RA. Myasthenia gravis and elderly people. Age Ageing. 1996;25:56-58.
9. Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry. 1998;64:78-83.
10. Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244:112-118.
11. Jacobson, DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223-243.
12. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand. 1984;70:274-284.
13. Osterman P. Current treatment of myasthenia gravis. Prog Brain Res. 1990;84:151-161.
14. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive population survey. Arch Neurol. 1991; 48:733-739.
15. Phillips LH II. The epidemiology of myasthenia gravis. Neurol Clin North Am. 1994; 12:263-271.
16. Walker A, Maltby T. Ageing Europe. Philadelphia, Pa: Open University Press; 1997.
17. Katzman R. The aging brain: limitations in our knowledge and future approaches. Arch Neurol. 1997;54:1201-1205.
18. Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological. HLA-antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103:579-601.
19. Aarli JA. Late onset myasthenia gravis. Eur J Neurol. 1997;4:203-209.
20. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology. 1990;40:786-790.
21. Somnier FE. Exacerbation of myasthenia gravis after removal of thymomas. Acta Neurol Scand. 1994;90:56-66.
22. Newsom-Davis J, Vincent A, Willcox N. Acetylcholine receptor antibody: clinical and experimental aspects. In: Receptors, Antibodies and Disease: Ciba Foundation Symposium 90. London, England: Pitman Books Ltd: 1982:225-247.
23. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJGH. Anti-acetylcholine receptor antibodies in myasthenia gravis. I: relation to clinical parameters in 250 patients. J Neurol Sci. 1983;58:357-370.
24. Kuks JBM. The Thymus and Myasthenia Gravis. Groningen, the Netherlands. Drukkerij Regenboog; 1992.
25. Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol. 1990;82:284-288.
26. Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B-cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest. 1992;66:331-336.
27. Skeie GO, Mygland Å, Aarli Ja, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity. 1995;20:99-104.
28. Somnier F, Trojaburg W. Neurophysiological evaluation in myasthenia gravis: a comprehensive study of a complete patient population. Electroencephalogr Clin Neurophysiol. 1993;89:73-87.
29. Keynes GK. Thymectomy for myasthenia gravis. Thorax 1949;4:126-148.
30. Olanow CW, Lane RJM, Roses AD. Thymectomy in late-onset myasthenia gravis. Arch Neurol. 1982;39:82-83.
31. Monden Y, Nakahara K, Fuji Y, et al. Myasthenia gravis in elderly patients. Ann Thorac Surg. 1985;39:433-436.